** Shares of the New York-based drug developer IN8bio INAB.O rises 17.5% to 31 cents
** Co says early-stage trial showed its experimental cancer therapy helped all 9 patients with a type of blood cancer remain in complete remission
** Co's therapy, INB-100, also helped increase survival rates of patients compared to historical data and the time they lived without their cancer worsening
** INAB was testing its therapy to treat acute myeloid leukemia, a cancer of the blood and bone marrow
** INB-100 uses gamma-delta T cells, that are rarely found in secondary lymphoid organs and play a role in helping control cancer activity, to target the disease
** Patients treated with INB-100 also showed prolonged and durable decrease in symptoms of their cancer beyond one year
** In the last 12 months, INAB has fallen 70.27%
(Reporting by Siddhi Mahatole)
((siddhiprabhanjan.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.